The evolving landscape of pulmonary arterial hypertension clinical trials

In treatment trials for pulmonary arterial hypertension, looking at clinical events as outcomes instead of just 6-minute walk distance requires longer studies with more participants. Given that PAH is a rare disease, finding large numbers of participants is a problem. Innovative trial designs offer new options while still providing good data.

Read the original journal article